Hsp90 inhibitor

Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612

Retrieved on: 
Tuesday, December 22, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Respiratory diseases, Cancer research, Medicine, Antiviral drugs, Medical specialties, Hsp90 inhibitor, Coronavirus disease, Severe acute respiratory syndrome, COVID-19 drug development

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory activity in SARS-CoV-2-infected primary human cells in preclinical studies.
  • The antiviral and anti-inflammatory activity of ADX-1612 demonstrated in COVID-19 models may be applicable to viral diseases generally, stated Emanuel Wyler, Ph.D., Research Scientist at MDC.
  • In May 2020, Dr. Wyler and colleagues identified HSP90 as a key antiviral target against SARS-CoV-21 and have confirmed the antiviral activity of ADX-1612, a potent HSP90 inhibitor, reported by Aldeyra earlier this year.
  • Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases.

Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors

Retrieved on: 
Tuesday, August 4, 2020
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Hsp90, Cancer research, Antineoplastic drugs, Branches of biology, Clinical medicine, Medicine, Monoclonal antibodies, Hsp90 inhibitor, Heat shock protein 90kDa alpha (cytosolic), member A1

Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced the publication of its preclinical study evaluating its HSP90 binding miniature drug conjugate with a pan-PI3K payload, T-2143, in solid tumors.

Key Points: 
  • Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced the publication of its preclinical study evaluating its HSP90 binding miniature drug conjugate with a pan-PI3K payload, T-2143, in solid tumors.
  • Its first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform.
  • Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors.
  • In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors.